Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525499 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by AndroScience.
- Completed
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
- 10
- Study locations
NCT00525499 is a Phase 2 study of Acne Vulgaris that has completed, run by AndroScience. The registered enrollment target is 186 participants, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (32% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT00525499, a Phase 2 study of Acne Vulgaris, has completed, sponsored by AndroScience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to evaluate if topical ASC-J9 cream is effective in treating acne.
Conditions Studied
Interventions
- DRUG placebo
- DRUG ASC-J9 cream
Study Locations (10)
California
- East Bay Dermatology Medical Group - Fremont
- Therapeutics Clinical Research - San Diego
Texas
- DermResearch, Inc - Austin
- J&S Studies, Inc - Bryan
Idaho
- Northwest Clinical Trial - Boise
New Jersey
- TKL Research, Inc - Paramus
New Mexico
- Academic Dermatology Associates - Albuquerque
Tennessee
- Dermatology Associates - Knoxville
Utah
- Dermatology Research Center, Inc - Salt Lake City
Virginia
- Education and Research Foundation - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00525499
The ClinicalTrials.gov registry entry for NCT00525499 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (32% lower). The listed sponsor is AndroScience, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00525499 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Texas, Idaho.
Frequently Asked Questions
What is clinical trial NCT00525499 about?
NCT00525499 is a clinical study titled "A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris". The purpose of this study is to evaluate if topical ASC-J9 cream is effective in treating acne.
What is the current status of trial NCT00525499?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2007-08. Estimated completion is 2008-07.
What conditions does trial NCT00525499 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT00525499?
The interventions under investigation include: placebo (DRUG), ASC-J9 cream (DRUG).
Who is sponsoring clinical trial NCT00525499?
This trial is sponsored by AndroScience, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00525499 being conducted?
This trial has 10 study locations across California, Idaho, New Jersey, New Mexico, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.